Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome

Aim. To conduct a comparative analysis of the effect of long-term pharmacotherapy (12 months) using a β-blocker (nebivolol) and its combination with eplerenone in patients after ST-segment elevation acute coronary syndrome (STE-ACS) with heart failure with mildly reduced ejection fraction (EF) (HFmr...

書目詳細資料
發表在:	Кардиоваскулярная терапия и профилактика
Main Authors:	O. A. Osipova, V. P. Mikhin, A. I. Golovin, O. N. Belousova, D. N. Perutsky, P. K. Alferov, S. L. Konstantinov
格式:	Article
語言:	俄语
出版:	«SILICEA-POLIGRAF» LLC 2022-07-01
主題:	st-segment elevation acute coronary syndrome heart failure with mildly reduced ejection fraction nebivolol eplerenone mineralocorticoid receptor antagonist
在線閱讀:	https://cardiovascular.elpub.ru/jour/article/view/3269

相似書籍

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy
由: Kapil G. Kapoor, et al.
出版: (2015-12-01)

Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
由: Sofia S. Pereira, et al.
出版: (2021-04-01)

Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: results of a two-year open-label extension trial
由: Subha V. Raman, et al.
出版: (2017-02-01)

Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis
由: Ahmed Elshahat, et al.
出版: (2024-09-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
由: O. M. Drapkina, et al.
出版: (2017-09-01)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
由: Akira Sezai, et al.
出版: (2025-05-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
由: A. G. Evdokimova, et al.
出版: (2023-01-01)

Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial
由: Masatake Kobayashi, et al.
出版: (2025-03-01)

A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist
由: Shuhui Zhai, et al.
出版: (2024-09-01)

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials
由: Jinfei Wu, et al.
出版: (2025-09-01)

Possible dose-dependent effect of eplerenone on intraocular pressure
由: Seyedeh Mehrsa Sadat Razavi, et al.
出版: (2023-01-01)

TRAITEMENT PAR ÉPLÉRÉNONE DANS LA CHORIORÉTINITE SÉREUSE CENTRALE CHRONIQUE : À PROPOS DE 8 CAS
由: A. El ouafi, et al.
出版: (2019-06-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
由: O. A. Osipova, et al.
出版: (2021-11-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
由: V. N. Soboleva, et al.
出版: (2015-01-01)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
由: Nina Vodošek Hojs, et al.
出版: (2021-06-01)

Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial
由: Niels H. Brandt-Jacobsen, et al.
出版: (2023-03-01)

Cardiac response to chronic restraint stress involves mineralocorticoid receptors in male Sprague–Dawley rats
由: D. Sztechman, et al.
出版: (2025-10-01)

Ocena skuteczności i bezpieczeństwa farmakoterapii inhibitorami aldosteronu w niewydolności serca = Evaluation of the efficacy and safety of pharmacotherapy using aldosterone antagonists in heart failure
由: Agata Tarczykowska, et al.
出版: (2015-07-01)

Dexamethasone-associated metabolic effects in male mice are partially caused by depletion of endogenous corticosterone
由: Lisa L. Koorneef, et al.
出版: (2022-08-01)

A Prospective Study of Eplerenone in the Treatment of Patients with Glomerulonephritis
由: Marios Papasotiriou, et al.
出版: (2023-12-01)

EVIDENCE-BASED USE OF EPLERENONE
由: S. R. Gilyarevski, et al.
出版: (2014-07-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
由: N. A. Nuritdinov, et al.
出版: (2020-12-01)

PHARMACOECONOMIC ASPECTS OF EPLERENONE USAGE IN CHRONIC HEART FAILURE
由: Yu. M. Lopatin, et al.
出版: (2015-08-01)

Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension
由: Mario Boehm, et al.
出版: (2018-03-01)

Effects of eplerenone on cerebral aldosterone levels and brain lesions in spontaneously hypertensive rats
由: Xue Wang, et al.
出版: (2020-08-01)

Mineralocorticoid receptor antagonists in heart failure: a systematic review and meta-analysis
由: Yue Zhang, et al.
出版: (2025-09-01)

New Clinical Aspects of Eplerenone Use in Clinical Practice
由: S. R. Gilyarevskiy, et al.
出版: (2018-09-01)

Influence of combined eplerenone, aflibercept and nepafenac therapy on central serous chorioretinopathy
由: Wael Ahmed Ewais, et al.
出版: (2025-06-01)

Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods
由: L. V. Shekhovtsova, et al.
出版: (2020-11-01)

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
由: A. Yu. Zharikov, et al.
出版: (2021-07-01)

Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone – a case report
由: Ramesh Venkatesh, et al.
出版: (2020-06-01)

Clinical outcome of eplerenone in the management of acute central serous chorioretinopathy
由: Pramod Kumar Sharma, et al.
出版: (2025-01-01)

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue
由: WEN Runzhi, WANG Li, ZHAO Naiqian
出版: (2025-06-01)

Combination of ADAM17 knockdown with eplerenone is more effective than single therapy in ameliorating diabetic cardiomyopathy
由: Lin Xie, et al.
出版: (2024-05-01)

A SELECTIVE ANTAGONIST OF MINERALOCORTICOID RECEPTOR EPLERENONE IN CARDIOLOGY PRACTICE
由: B. B. Gegenava, et al.
出版: (2015-09-01)

Oral Eplerenone Versus Observation in the Management of Acute Central Serous Chorioretinopathy: A Prospective, Randomized Comparative Study
由: Ramesh Venkatesh, et al.
出版: (2020-07-01)

Real-world practice patterns of eplerenone use for central serous chorioretinopathy
由: Ramesh Venkatesh, et al.
出版: (2023-10-01)

Benefit of combination therapy with dapagliflozin and eplerenone on cardiac function and fibrosis in rats with non-diabetic chronic kidney disease
由: M. Soulié, et al.
出版: (2024-10-01)

A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure
由: C McKenna, et al.
出版: (2010-05-01)

Dynamics of fibrotic and vascular endothelial dysfunction markers in elderly hypertensive patients after ischemic stroke receiving beta-blockers
由: O. A. Osipova, et al.
出版: (2022-01-01)